Post-Streptococcal Glomerulonephritis (PSGN)

1. Executive Overview: Understanding PSGN

Post-Streptococcal Glomerulonephritis (PSGN) is a classic manifestation of acute nephritic syndrome, occurring secondary to an infection with nephritogenic strains of Group A beta-hemolytic Streptococcus (GAS), specifically Streptococcus pyogenes. While often perceived as a pediatric condition, PSGN represents a significant immunological challenge to the renal parenchyma, characterized by the deposition of immune complexes within the glomerular basement membrane (GBM).

Clinically, PSGN is defined by the sudden onset of hematuria, proteinuria, hypertension, and edema. It is a quintessential example of an immune-complex-mediated glomerulonephritis. Unlike tubular pathologies, which often present with electrolyte wasting or polyuria, PSGN is a glomerular injury that rapidly compromises the filtration surface, leading to a precipitous decline in the estimated Glomerular Filtration Rate (eGFR) and retention of nitrogenous wastes.

2. Pathophysiology, Etiology, and Risk Factors

The Immunological Mechanism

The pathogenesis of PSGN is rooted in a Type III hypersensitivity reaction. The infection (typically pharyngitis or impetigo) triggers the formation of circulating immune complexes or, more commonly, the in situ formation of complexes involving streptococcal antigens such as Nephritis-Associated Plasmin Receptor (NAPlr) or Streptococcal Pyrogenic Exotoxin B (SPEB).

These antigens become trapped in the subepithelial space of the glomerulus. This triggers:
1. Complement Activation: Classic and alternative pathways are activated, leading to low serum C3 levels.
2. Inflammatory Cascade: Infiltration of neutrophils and macrophages into the glomerular tuft.
3. Proliferative Response: Mesangial and endothelial cell proliferation, which reduces the effective surface area for filtration.

Glomerular vs. Tubular Pathology

3. Clinical Presentation: Nephritic vs. Nephrotic Spectrum

PSGN typically presents as an acute nephritic syndrome. The classic triad includes:
* Hematuria: Often described as "cola-colored" or "tea-colored" urine due to the breakdown of red blood cells in the acidic environment of the distal tubule.
* Hypertension: Secondary to sodium and water retention resulting from the sudden reduction in eGFR.
* Edema: Periorbital edema is the most common early sign, progressing to peripheral edema or pulmonary congestion in severe cases.

While PSGN is primarily nephritic, some patients may exhibit "nephrotic-range" proteinuria (exceeding 3.5g/1.73m² per day). This occurs when the inflammatory damage to the podocytes is extensive enough to disrupt the charge-selective barrier of the GBM.

4. Diagnostic Evaluation and Workup

Diagnostic criteria rely on the temporal relationship between a streptococcal infection and the onset of renal symptoms.

Laboratory Assays

• Serology: Elevated Anti-Streptolysin O (ASO) titers or Anti-DNase B levels.
• Complement Profile: Hypocomplementemia (low serum C3) is a hallmark of PSGN. C4 levels are typically normal, distinguishing PSGN from Lupus Nephritis.
• Renal Function: Serial monitoring of serum creatinine and eGFR is mandatory. A rapid rise in creatinine signifies an acute kidney injury (AKI) secondary to glomerular inflammation.

Imaging and Biopsy

Imaging (Renal Ultrasound) is used primarily to rule out obstructive uropathy or chronic kidney disease (CKD) features like cortical thinning.

Indications for Renal Biopsy:
1. Persistent oliguria or anuria.
2. Progressive rise in creatinine despite conservative management.
3. Proteinuria persisting for > 6 months.
4. Absence of evidence of recent streptococcal infection.
5. Persistent hypocomplementemia beyond 8 weeks.

Biopsy Findings: On light microscopy, the glomeruli appear enlarged and hypercellular. Immunofluorescence typically shows "lumpy-bumpy" deposits of IgG and C3. Electron microscopy reveals subepithelial "humps."

5. Therapeutic Interventions and Management

Management is primarily supportive, adhering to the principles of nephroprotection and fluid balance.

Pharmacological and Supportive Care

• Fluid Management: Restriction of sodium and water intake to manage hypertension and edema.
• Diuretics: Loop diuretics (e.g., furosemide) are indicated for volume overload and hypertension.
• Antihypertensives: Calcium channel blockers or ACE inhibitors are preferred, provided the eGFR is stable.
• Antibiotics: A course of penicillin or appropriate antibiotic is indicated to eradicate any residual streptococcal reservoir, preventing transmission, even if it does not alter the course of the established nephritis.

Systemic Consequences (CKD-MBD and Uremia)

In severe, prolonged cases, patients may develop manifestations of uremia (nausea, altered mental status, pericarditis). While CKD-Mineral and Bone Disorder (CKD-MBD) is rare in acute PSGN, chronic cases require monitoring of serum calcium, phosphate, and PTH levels.

KDIGO Staging and Pathway

While KDIGO guidelines focus primarily on CKD, the principles of AKI management apply here:
1. Stage 1: Close monitoring of urine output and serum creatinine.
2. Stage 2/3: Consideration for renal replacement therapy (RRT) if severe hyperkalemia, refractory volume overload, or severe acidosis develops.

6. Frequently Asked Questions (FAQ)

1. Is PSGN the same as IgA Nephropathy?
No. IgA nephropathy is characterized by IgA deposits, while PSGN is characterized by IgG and C3 "lumpy-bumpy" deposits.

2. Does PSGN always lead to chronic kidney failure?
In children, the prognosis is excellent with over 95% recovery. In adults, the risk of developing chronic hypertension or CKD is higher.

3. Why is my urine tea-colored?
The color is caused by the presence of red blood cells that have been damaged as they pass through the inflamed glomerular filters.

4. Can I prevent PSGN?
Early and complete treatment of streptococcal pharyngitis and skin infections (impetigo) with appropriate antibiotics is the primary prevention strategy.

5. How long does it take for C3 levels to normalize?
Serum C3 levels typically return to normal within 6 to 8 weeks following the acute phase.

6. Do I need a kidney biopsy to diagnose PSGN?
Not always. In classic presentations in children with clear evidence of recent infection, a biopsy is often unnecessary.

7. Can PSGN recur?
Recurrence is extremely rare, as immunity to the specific nephritogenic strain develops.

8. What is the role of steroids in PSGN?
Corticosteroids are generally not recommended for PSGN, as they do not show benefit in the acute inflammatory phase and may increase infection risk.

9. How does hypertension occur in PSGN?
It is primarily "volume-dependent" hypertension resulting from the kidneys' inability to excrete sodium and water.

10. When should I see a nephrologist?
Immediate consultation is required if you experience a sudden decrease in urine volume, severe swelling, or high blood pressure following a throat or skin infection.

Disclaimer: This guide is intended for educational purposes and reflects clinical standards as of the current date. It is not a substitute for professional medical diagnosis or treatment. Always consult with a board-certified nephrologist for personalized clinical management.

Related Clinical Integration

In the management of Post-Streptococcal Glomerulonephritis (PSGN), a systematic clinical approach is required to confirm the diagnosis and manage associated complications. Diagnostic evaluation typically begins with a Urinalysis to assess for hematuria and proteinuria, followed by Antistreptolysin O (ASO) Titer to confirm recent streptococcal infection, and monitoring of renal function via Blood Urea Nitrogen (BUN) Measurement and Serum Creatinine Measurement; in cases of atypical presentation or progressive decline, a Renal biopsy may be indicated. Therapeutic intervention focuses on eradicating the underlying pathogen using Penicillin G Benzathine or Retarpin / ريتاربين 1,200,000 IU, while supportive care for hypertension and edema involves the use of Diuretics, specifically Furosemide / فوروسيميد 40mg, and antihypertensive agents such as Lisinopril / ليسينوبريل 10mg. While Prednisolone / بريدنيزولون Standard is generally reserved for specific inflammatory contexts, clinicians should maintain a broad focus on systemic health,